Exenatide vs Semaglutide
Written by Aaron CuhaReviewed Sep 2026
The short answer
The first GLP-1 drug to reach the market, against the one that pushed it aside, tested directly in their weekly forms.
- Exenatide people
- 15,088
- Exenatide nulls
- 1
- Semaglutide people
- 42,363
- Semaglutide nulls
- 2
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Byetta, Bydureon)
Dose
Approved titration: 0.25, 0.5, 1, 1.7 and 2.4 mg
0.25, 0.5, 1, 1.7 and 2.4 mg
The approved semaglutide ladder, in mg.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
ExenatideExenatide (GLP-1 receptor agonist)
The first approved drug in the GLP-1 family. It is based on a hormone found in Gila monster spit, and it opened the door for the whole drug family.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.
These two were tested against each other in the same trial
One trial gave people each of them. This is not us lining up two separate records.
HbA1c fell 1.5 points on semaglutide against 0.9 on long acting exenatide, an estimated gap of 0.62 points. Weight fell 5.6 kg against 1.9 kg, a gap of 3.78 kg. Both gaps were clear. 67 percent against 40 percent got their HbA1c below 7.0 percent. Stomach and gut side effects were more common on semaglutide, 41.8 against 33.3 percent. Reactions at the shot site were more common on exenatide, 22.0 against 1.2 percent.
What the trial was
A large final stage trial. Everyone knew which drug they were on. 813 adults with type 2 diabetes taking diabetes pills were split evenly between once weekly semaglutide 1.0 mg or long acting exenatide 2.0 mg for 56 weeks. The main measure was the change in HbA1c, a three month blood sugar reading, at week 56. On average people started at an HbA1c of 8.3 percent and a weight of 95.8 kg.
What the authors concluded
The authors state that semaglutide 1.0 mg beat long acting exenatide 2.0 mg at controlling blood sugar and cutting body weight at 56 weeks, with similar safety.
Where this result is weak
Everyone knew which drug they were on, so the side effect comparison in particular rests on reports from people who knew. It ran 56 weeks in people with type 2 diabetes on diabetes pills. It measured HbA1c and weight, not heart problems or deaths. It was paid for by Novo Nordisk, which makes the drug that won. And it used semaglutide 1.0 mg, a diabetes dose rather than the 2.4 mg used for weight loss.
Side by side, on the facts we can check
| What we compare | Exenatide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Byetta, Bydureon) | FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~2.4 hours (immediate release) | ~7 days |
| Molecular weight | 4,186.6 Da | 4,113.6 Da |
| How it works | It copies GLP-1, a gut hormone. It is about 53% the same as the human version. It helps your body release insulin, turns down glucagon (a hormone that raises blood sugar) and slows how fast food leaves your stomach. | It switches on the GLP-1 receptor, a switch on cells that normally answers a gut hormone after you eat. That makes the body release insulin when blood sugar is high. It holds back glucagon, a hormone that raises blood sugar. It slows how fast the stomach empties. It also acts on the part of the brain that runs hunger, so people eat less. |
| Studies in people | 2 | 15 |
| Evidence | Strong: 2 completed trials, 15,088 people given it | Strong: 12 completed trials, 42,363 people given it |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Exenatide and Semaglutide?
Exenatide: The first approved drug in the GLP-1 family. It is based on a hormone found in Gila monster spit, and it opened the door for the whole drug family. Semaglutide: A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.
Which has stronger research evidence, Exenatide or Semaglutide?
Each compound gets a band worked out from facts we counted, with the math shown. Exenatide is Strong (2 completed trials, 15,088 people given it). Semaglutide is Strong (12 completed trials, 42,363 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Exenatide and Semaglutide FDA-approved?
Exenatide: FDA-approved (Byetta, Bydureon). Semaglutide: FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Exenatide or Semaglutide, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.